Browse press releases

The newest releases come first, each with its full text here and a link to its original. Try the filters to narrow them down.

1,787 resultsPage 72 of 149, newest first

Sep 18 UTCEnergyMango PowerMango Power S Earns UL 3700 Certification for Interactive Plug-In Solar ApplicationsBuilding on UL 1741, IEEE 1547 and CEC listing, Mango Power S combines 97% CEC efficiency, single-stage Cyclo topology and intelligent anti-backflow control for a simpler owner-led solar experience — Mango Power, a clean energy technology company and...
Sep 17 UTCEnergyA股限售股解禁一览：19.28亿元市值限售股今日解禁格隆汇9月18日｜Wind数据显示，周五（9月18日），共有11家公司限售股解禁，合计解禁量为7451.33万股，按最新收盘价计算，合计解禁市值为19.28亿元。从解禁量来看，*ST美丽、金帝股份、晶丰明源解禁量居前，解禁股数分别为3382.14万股、3300.0万股、324.54万股。从解禁市值来看，金帝股份、晶丰明源、安克创新解禁市值居前，解禁市值分别为12.04亿元、4.56亿元、1.73亿...
Sep 17 UTCFinanceRiyadh Global Medical Biotechnology Summit 2026 Closes as a Major Success with SAR 5.5 Billion in Agreements and announcement, Confirming Saudi Arabia's Commitment to Lead the Future of BiotechnologyRIYADH, KSA, Sept 18, 2026 - The Riyadh Global Medical Biotechnology Summit closed today as a major success in its fourth edition and a clear statement of the scale of Saudi Arabia's ambition in biotechnology. Over three days, more than 15,000 visitors from more than 57 countries and more than 200 speakers across more than 70 sessions saw that ambition turned into more than 40 agreements, initiatives, and announcements with a combined declared value of more than SAR 5 billion (USD 1.33 billion), up from more than USD 100 million in deal value generated at the 2024 edition. Partners came from Spain, China, Japan, Germany, the United States, South Korea, Denmark, and Malaysia to join the Kingdom's leading universities, research centers, and manufacturers at the Sofitel Riyadh Hotel and Convention Centre, where more than 120 sponsors and exhibitors filled 6,000 square meters of event space and more than 180 strategic meetings took place. More than 40 agreements and announcements, initiatives, and announcements worth more than SAR 5 billion (USD 1.33 billion) delivered on every pillar of the Summit, from national strategy and regulation to investment, research readiness, and talent, with participants from more than 57 countries in Riyadh. The Summit opened on 14 September under the patronage of His Royal Highness Prince Mohammed bin Salman bin Abdulaziz Al Saud, Crown Prince and Prime Minister, and was inaugurated by His Royal Highness Prince Abdullah bin Bandar bin Abdulaziz, Minister of National Guard. His Excellency Prof. Bandar Alknawy MD , FRCPC CEO of the Ministry of National Guard Health Affairs (MNGHA) and President of King Saud bin Abdulaziz University for Health Sciences (KSAU-HS), and King Abdullah International Medical Research Center (KAIMRC) Chairman of RGMBS, addressed the opening ceremony, describing the Summit as a platform for advancing the National Biotechnology Strategy launched by His Royal Highness the Crown Prince in January 2024, at a time of rapid and far-reaching discovery in the field. Her Royal Highness Princess Dr. Maha bint Mishari bin Abdulaziz Al Saud, Chief Executive Officer of the FII Institute, addressed the opening ceremony. Her Royal Highness highlighted the role of capital, ideas, and long-term alliances in turning scientific breakthroughs into lasting impact on humanity. She placed the human purpose of the field at the center of the Summit's work: extending not only the length of life but its quality, so that patients gain more time, and better time, with the people they love. FOUR PILLARS, ONE NATIONAL MISSION RGMBS 2026 was built on four pillars under the theme Building the Foundations of Biotechnology Excellence, with each pillar explored through scientific, panel, and executive sessions. Governmental strategies and regulatory support. KAIMRC and the Ministry of Investment launched BioSync. The one stop shop for every biotech investor, consolidating the Kingdom's entire life sciences ecosystem into a single, authoritative platform. Regulators and scientists shared the stage throughout the program, culminating in a Day Three panel on regulation as an enabling scientific tool. Investment and funding. Vaccine Industrial Company confirmed that its human vaccine manufacturing facility, a SAR 500 million investment across 42,000 square meters, is 85 percent complete and is planned to localize up to 80 percent of the Kingdom's essential vaccine needs. Sanabil Studio by Redesign Health signed with Telepath by Tahlili on AI and digital pathology, with a potential investment of USD 3 million, and the Life Sciences Innovation Forum drew applications from more than 100 companies, nominated more than 25 for investment, and engaged five investment funds willing to invest with a combined value of more than USD 120 million. Research and development readiness. King Abdullah International Medical Research Center (KAIMRC) and Thermo Fisher Scientific announced a Center of Excellence for Genomics, Proteomics, and Biobanking. The University Hospitals Program at the Council of Universities' Affairs signed with Novo Nordisk to build clinical trial capability, including earlier phase trials. KAIMRC also agreed research collaborations with Olink in proteomics, Tiziana Life Sciences in immunomodulation and neuroimmunology, and Japan's Chiyoda Corporation in plant-based peptide production for cancer treatment. King Saud University and BioMe of South Korea signed to establish a microbiome joint venture, the University of Hafr Al Batin partnered with BGI Group, and Najran University launched the Najran Genomic Biobank Initiative. Building capabilities. KAIMRC signed with Rutgers University on a summer school, master's programs, and research in artificial intelligence, and with LeapUp on training and capacity building. Princess Nourah bint Abdulrahman University and Cellenkos launched a program to develop Saudi female talent in cell and gene therapy and biomanufacturing, and SVAX and Batterjee Medical College agreed accredited biomanufacturing training with up to 350 seats per cycle. King Saud University launched four national initiatives, including an annual Saudi International Biotechnology Conference and the KSU BioHack hackathon. THREE DAYS ON THE MAIN STAGE Day One: The program opened with the National Biotechnology Strategy and a session on global partnership with Dr. Steve Yang of WuXi AppTec, Mr. Alec Reynolds of Flagship Pioneering, and Prof. Ahmed Alaskar of KAIMRC, before turning to AI in biotechnology and multi-omics, including Prof. Jin-Soo Kim of KAIST on mitochondrial DNA editing beyond CRISPR. Day Two: Investment, immunology, and bioengineering took the stage, with Mr. Kasim Kutay of Novo Holdings on investing in AI, Prof. Keith T. Flaherty, President of the American Association for Cancer Research, on cancer immunology, Astronaut Rayyanah Barnawi on the human immune system in space, and Dr. Matthew H. Porteus of Stanford University on CRISPR-engineered cell-based drugs. Day Three: The final day focused on the biotechnology workforce and regulation, a closing keynote from Dr. Hyun-Young Park, Deputy Minister of the Korea National Institute of Health, ahead of the closing ceremony. "RGMBS 2026 has shown the world what Saudi Arabia means when it says biotechnology is a national mission. We named this edition for foundations, and over three days those foundations were laid in full view: a vaccine plant nearing completion, a genomics center with Thermo Fisher, clinical trials with Novo Nordisk, and training for a new generation of Saudi scientists, each with a named partner and a defined scope. "Under the direction of our leadership and the National Biotechnology Strategy, the Kingdom is committed to leading this field for decades to come. We will measure that leadership by one standard above all: the difference it makes to the lives of patients and their families." H.E Bandar Alknawy MD , FRCPC CEO of the Ministry of National Guard Health Affairs (MNGHA) and President of KSAU-HS and KAIMRC Chairman of RGMBS . RGMBS 2026 was organized and supervised by the Ministry of National Guard, represented by its Health Affairs sector, and hosted by King Saud bin Abdulaziz University for Health Sciences (KSAU-HS), and King Abdullah International Medical Research Center (KAIMRC), with the Ministry of Investment, Invest Saudi, and the FII Institute serving as strategic partners. The commitments made in Riyadh advance the National Biotechnology Strategy, which targets a USD 34.6 billion contribution to non-oil GDP from biotechnology by 2040, and confirm the Kingdom's place at the forefront of global biotechnology in the years ahead. About The Riyadh Global Medical Biotechnology Summit The Riyadh Global Medical Biotechnology Summit is the Kingdom of Saudi Arabia's flagship platform for medical biotechnology, convening the global scientific, investment, and policy communities in Riyadh. Organized and supervised by the Ministry of National Guard, represented by its Health Affairs sector, and hosted by KAIMRC and KSAU-HS, the Summit advances the goals of the National Biotechnology Strategy and supports the Kingdom's emergence as a global destination for health innovation. The fourth edition took place from 14 to 16 September 2026 in Riyadh. rgmbs.org FOR FURTHER INFORMATION Email: [email protected] Telephone: +966 559 810 777
Sep 17 UTCCryptoZhou Jianjun, de Huawei : concevoir une solution AIDC connectée au réseau pour optimiser le rendement token/wattCompanies: HuaweiSHENZHEN, Chine, 18 septembre 2026 -- L'expo 2026 Green Energy Development Conference & International Digital Energy vient d'ouvrir ses portes à Shenzhen. Zhou Jianjun, vice-président de Huawei et président du marketing, des ventes et des services de Huawei Digital Power, a...
Sep 17 UTCFinanceHagens Berman Sobol Shapiro LLPFCEL ALERT: Hagens Berman Reminds FuelCell Energy Investors of November 10, 2026 Lead Plaintiff DeadlineNational trial law firm Hagens Berman alerts investors in FuelCell Energy, Inc. (NASDAQ: FCEL) that a securities class action has been filed, and reminds investors that they have until November 10, 2026, to seek appointment as lead plaintiff....
Sep 17 UTCFinanceRiyadh Global Medical Biotechnology Summit 2026 Closes as a Major Success with SAR 5.5 Billion in Agreements and announcement, Confirming Saudi Arabia's Commitment to Lead the Future of BiotechnologyRIYADH, KSA, Sept 18, 2026 - The Riyadh Global Medical Biotechnology Summit closed today as a major success in its fourth edition and a clear statement of the scale of Saudi Arabia's ambition in biotechnology. Over three days, more than 15,000 visitors from more than 57 countries and more than 200 speakers across more than 70 sessions saw that ambition turned into more than 40 agreements, initiatives, and announcements with a combined declared value of more than SAR 5 billion (USD 1.33 billion), up from more than USD 100 million in deal value generated at the 2024 edition. Partners came from Spain, China, Japan, Germany, the United States, South Korea, Denmark, and Malaysia to join the Kingdom's leading universities, research centers, and manufacturers at the Sofitel Riyadh Hotel and Convention Centre, where more than 120 sponsors and exhibitors filled 6,000 square meters of event space and more than 180 strategic meetings took place. More than 40 agreements and announcements, initiatives, and announcements worth more than SAR 5 billion (USD 1.33 billion) delivered on every pillar of the Summit, from national strategy and regulation to investment, research readiness, and talent, with participants from more than 57 countries in Riyadh. The Summit opened on 14 September under the patronage of His Royal Highness Prince Mohammed bin Salman bin Abdulaziz Al Saud, Crown Prince and Prime Minister, and was inaugurated by His Royal Highness Prince Abdullah bin Bandar bin Abdulaziz, Minister of National Guard. His Excellency Prof. Bandar Alknawy MD , FRCPC CEO of the Ministry of National Guard Health Affairs (MNGHA) and President of King Saud bin Abdulaziz University for Health Sciences (KSAU-HS), and King Abdullah International Medical Research Center (KAIMRC) Chairman of RGMBS, addressed the opening ceremony, describing the Summit as a platform for advancing the National Biotechnology Strategy launched by His Royal Highness the Crown Prince in January 2024, at a time of rapid and far-reaching discovery in the field. Her Royal Highness Princess Dr. Maha bint Mishari bin Abdulaziz Al Saud, Chief Executive Officer of the FII Institute, addressed the opening ceremony. Her Royal Highness highlighted the role of capital, ideas, and long-term alliances in turning scientific breakthroughs into lasting impact on humanity. She placed the human purpose of the field at the center of the Summit's work: extending not only the length of life but its quality, so that patients gain more time, and better time, with the people they love. FOUR PILLARS, ONE NATIONAL MISSION RGMBS 2026 was built on four pillars under the theme Building the Foundations of Biotechnology Excellence, with each pillar explored through scientific, panel, and executive sessions. Governmental strategies and regulatory support. KAIMRC and the Ministry of Investment launched BioSync. The one stop shop for every biotech investor, consolidating the Kingdom's entire life sciences ecosystem into a single, authoritative platform. Regulators and scientists shared the stage throughout the program, culminating in a Day Three panel on regulation as an enabling scientific tool. Investment and funding. Vaccine Industrial Company confirmed that its human vaccine manufacturing facility, a SAR 500 million investment across 42,000 square meters, is 85 percent complete and is planned to localize up to 80 percent of the Kingdom's essential vaccine needs. Sanabil Studio by Redesign Health signed with Telepath by Tahlili on AI and digital pathology, with a potential investment of USD 3 million, and the Life Sciences Innovation Forum drew applications from more than 100 companies, nominated more than 25 for investment, and engaged five investment funds willing to invest with a combined value of more than USD 120 million. Research and development readiness. King Abdullah International Medical Research Center (KAIMRC) and Thermo Fisher Scientific announced a Center of Excellence for Genomics, Proteomics, and Biobanking. The University Hospitals Program at the Council of Universities' Affairs signed with Novo Nordisk to build clinical trial capability, including earlier phase trials. KAIMRC also agreed research collaborations with Olink in proteomics, Tiziana Life Sciences in immunomodulation and neuroimmunology, and Japan's Chiyoda Corporation in plant-based peptide production for cancer treatment. King Saud University and BioMe of South Korea signed to establish a microbiome joint venture, the University of Hafr Al Batin partnered with BGI Group, and Najran University launched the Najran Genomic Biobank Initiative. Building capabilities. KAIMRC signed with Rutgers University on a summer school, master's programs, and research in artificial intelligence, and with LeapUp on training and capacity building. Princess Nourah bint Abdulrahman University and Cellenkos launched a program to develop Saudi female talent in cell and gene therapy and biomanufacturing, and SVAX and Batterjee Medical College agreed accredited biomanufacturing training with up to 350 seats per cycle. King Saud University launched four national initiatives, including an annual Saudi International Biotechnology Conference and the KSU BioHack hackathon. THREE DAYS ON THE MAIN STAGE Day One: The program opened with the National Biotechnology Strategy and a session on global partnership with Dr. Steve Yang of WuXi AppTec, Mr. Alec Reynolds of Flagship Pioneering, and Prof. Ahmed Alaskar of KAIMRC, before turning to AI in biotechnology and multi-omics, including Prof. Jin-Soo Kim of KAIST on mitochondrial DNA editing beyond CRISPR. Day Two: Investment, immunology, and bioengineering took the stage, with Mr. Kasim Kutay of Novo Holdings on investing in AI, Prof. Keith T. Flaherty, President of the American Association for Cancer Research, on cancer immunology, Astronaut Rayyanah Barnawi on the human immune system in space, and Dr. Matthew H. Porteus of Stanford University on CRISPR-engineered cell-based drugs. Day Three: The final day focused on the biotechnology workforce and regulation, a closing keynote from Dr. Hyun-Young Park, Deputy Minister of the Korea National Institute of Health, ahead of the closing ceremony. "RGMBS 2026 has shown the world what Saudi Arabia means when it says biotechnology is a national mission. We named this edition for foundations, and over three days those foundations were laid in full view: a vaccine plant nearing completion, a genomics center with Thermo Fisher, clinical trials with Novo Nordisk, and training for a new generation of Saudi scientists, each with a named partner and a defined scope. "Under the direction of our leadership and the National Biotechnology Strategy, the Kingdom is committed to leading this field for decades to come. We will measure that leadership by one standard above all: the difference it makes to the lives of patients and their families." H.E Bandar Alknawy MD , FRCPC CEO of the Ministry of National Guard Health Affairs (MNGHA) and President of KSAU-HS and KAIMRC Chairman of RGMBS . RGMBS 2026 was organized and supervised by the Ministry of National Guard, represented by its Health Affairs sector, and hosted by King Saud bin Abdulaziz University for Health Sciences (KSAU-HS), and King Abdullah International Medical Research Center (KAIMRC), with the Ministry of Investment, Invest Saudi, and the FII Institute serving as strategic partners. The commitments made in Riyadh advance the National Biotechnology Strategy, which targets a USD 34.6 billion contribution to non-oil GDP from biotechnology by 2040, and confirm the Kingdom's place at the forefront of global biotechnology in the years ahead. About The Riyadh Global Medical Biotechnology Summit The Riyadh Global Medical Biotechnology Summit is the Kingdom of Saudi Arabia's flagship platform for medical biotechnology, convening the global scientific, investment, and policy communities in Riyadh. Organized and supervised by the Ministry of National Guard, represented by its Health Affairs sector, and hosted by KAIMRC and KSAU-HS, the Summit advances the goals of the National Biotechnology Strategy and supports the Kingdom's emergence as a global destination for health innovation. The fourth edition took place from 14 to 16 September 2026 in Riyadh. rgmbs.org FOR FURTHER INFORMATION Email: [email protected] Telephone: +966 559 810 777
Sep 17 UTCEnergyHemisphere Energy CorporationHemisphere Energy Provides Operations UpdateHemisphere Energy Corporation (TSXV: HME) (OTCQX: HMENF) ("Hemisphere" or the "Company") provides an update on its operations at Marsden, Saskatchewan and Atlee Buffalo, Alberta.Marsden, SaskatchewanHemisphere recently drilled two successful horizontal wells targeting the Colony Formation in the Marsden area. The wells have been on production for three weeks at approximately 100 bbl/d each (100% heavy oil, based on field...
Sep 17 UTCEnergyWestgate Energy Inc. Announces Upsizing of Bought Deal LIFE Offering to $6.5 MillionTHIS PRESS RELEASE IS NOT FOR DISTRIBUTION TO UNITED STATES NEWS WIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES.
Sep 17 UTCEnergyVORTEXVortex Energy Enters Into Asset Purchase Agreement to Acquire the Meadows Project in SaskatchewanVortex Energy Corp. (CSE: VRTX) (OTC: VTECF) (FSE: AA3) (“Vortex” or the “Company”) is pleased to announce that it has entered into an asset purchase agreement (the “Asset Purchase Agreement”) with Global Strategic Minerals Corp. (the “Vendor”), pursuant to which the Company will acquire (the “Transaction”) the Purchased Assets (as defined below) comprising the Meadows Project (the “Project”) located in west-central Saskatchewan near the Alberta border (the “Meadows Project”).
Sep 17 UTCFinanceKaplan Fox & Kilsheimer LLPKaplan Fox Encourages FuelCell Energy, Inc. (FCEL) Investors with Significant Losses to Contact the Firm Before November 10, 2026Kaplan Fox & Kilsheimer LLP announces that a class action lawsuit has been filed against FuelCell Energy, Inc. ("FuelCell" or the "Company") (NASDAQ: FCEL) on behalf of investors that purchased or otherwise acquired FuelCell securities between June 24, 2026 and September 1, 2026 (the "Class Period").CLICK HERE TO JOIN THE CASEIf you are an investor in FuelCell and have suffered losses, you may CLICK HERE to contact us. You may also...
Sep 17 UTCEnergyZhou Jianjun van Huawei: Een netinteractieve AIDC-oplossing bouwen om het aantal tokens per watt te maximaliserenCompanies: HuaweiSHENZHEN, China, 17 september 2026 -- De Green Energy Development Conference & International Digital Energy Expo 2026 is in Shenzhen van start gegaan. Zhou Jianjun, vice-president van Huawei en president van Global Marketing, Sales and Services van Huawei Digital Power,...
Sep 17 UTCFinanceKaplan Fox & Kilsheimer LLPKaplan Fox & Kilsheimer LLP Alerts Bloom Energy Corporation (BE) Investors to Their Right to Seek Lead Plaintiff Status Before September 28, 2026Kaplan Fox & Kilsheimer LLP announces that a class action lawsuit has been filed against Bloom Energy Corporation ("Bloom Energy" or the "Company") (NYSE: BE) on behalf of investors that purchased or otherwise acquired Bloom Energy securities between February 27, 2025 and July 8, 2026 (the "Class Period").CLICK HERE TO JOIN THE CASEIf you are an investor in Bloom Energy and have suffered losses, you may CLICK HERE to contact us. You may...